Navigation Links
Nventa Appoints John Varian to Board of Directors
Date:5/7/2008

- New Member Complements Board With Significant Financial and Operational

Expertise -

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of John Varian to the company's board of directors. Mr. Varian currently serves as the chief operating officer and chief financial officer of Aryx Therapeutics, a pharmaceutical company focused on the discovery and development of oral therapeutics for chronic disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are very pleased to welcome John to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His extensive experience in helping companies establish strategic direction, raise venture and public capital, and negotiate successful alliances and acquisitions should be extremely beneficial to Nventa as it grows internally and continues its path to commercializing its first product."

Prior to joining Aryx Therapeutics, Mr. Varian was chief financial officer of Genset S.A., where he was a key member of the team negotiating the company's sale to Serono S.A. in 2002. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation's chief financial officer from June 1997 until October 1998. Mr. Varian is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference.

"I am proud to join the board at Nventa Biopharmaceuticals, a truly innovative company that is working to bring much needed therapeutic options to patients affected by HPV-related diseases," stated Mr.
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventas CEO to present at two upcoming investor conferences
6. Nventa announces publication of HspE7 data
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Kendle Appoints Patricia Williams Vice President, Commercial Operations
9. Biomoda Appoints Three Business Leaders to Board of Directors
10. Shengtai Pharmaceutical, Inc. Appoints New CFO
11. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NIAGARA FALLS, N.Y., Jan. 15, 2014   Niagara ... has been selected by Buffalo BioBlower Technologies LLC ("B3") ... its SBIR Phase 2 award from the Army Corps ... purification system that kills all biological contaminants and destroys ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... PharmAthene, Inc. (NYSE Amex: PIP ) ... the development of its second generation anthrax vaccine, SparVax™. ... 100 liter scale and demonstrating 36 month stability, the ... 1,500 liter engineering production run for SparVax™.  As a ...
... Sept. 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... the Rodman & Renshaw Annual Global Investment Conference on Tuesday, ... will be held at The Waldorf Astoria in New York, ... Executive Officer of Palatin Technologies, will provide an update on ...
... England, September 9, 2011 PharmaVentures ... to announce that they have been engaged by ... a buyer for an established full service CMC ... Pleasanton, California. The engagement will utilise PharmaVentures, asset ...
Cached Biology Technology:PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program 2PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program 3PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program 4
(Date:7/9/2014)... of the puzzle behind nature,s ability to split ... advance the development of artificial photosynthesis for clean, ... an international collaboration of scientists led by researchers ... and the SLAC National Accelerator Laboratory. , ... the world,s most powerful x-ray laser, the researchers ...
(Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bee foraging chronically impaired by pesticide exposure: Study 2
... and vegetables that are rich in nitrates protect the ... nitrates into nitrites by the bacteria in the oral ... in the stomach. The Swedish researcher Joel Petersson has ... can be harmful for the stomach. "Nitrates in ...
... behind mad cow disease and its human variation, Creutzfeldt-Jakob ... findings from Gerald Zamponi and colleagues, normally functioning prions ... appear in the May 5th issue of the Journal ... when the prion protein adopts an abnormal conformation. This ...
... in Support of "New Employee,Verification Act", ALEXANDRIA, ... to human resource management today led a coalition ... "New Employee,Verification Act." In testimony today before the ... Meisinger, President and CEO of SHRM,urged legislators to ...
Cached Biology News:Nitrates in vegetables protect against gastric ulcers 2Nitrates in vegetables protect against gastric ulcers 3Nitrates in vegetables protect against gastric ulcers 4Nitrates in vegetables protect against gastric ulcers 5SHRM CEO Testifies Before House Subcommittee on Social Security 2SHRM CEO Testifies Before House Subcommittee on Social Security 3
...
...
... Novagen's frozen Sf9 Insect Cells are derived from ... pretested for optimal growth, use in transfections, plaque ... are frozen in a protocol that optimizes recovery ... for growth in serum-free BacVector Insect Cell Medium ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: